ejpmr, 2025, 12(3), 122-133

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

PHARMACOVIGILANCE: THE BACKBONE OF DRUG SAFETY WITH SPECIAL REFERENCE TO THE MONKEYPOX VIRUS

[1]Himanee Takzare and [2]*Dr. D. K. Jain

Department of Pharmacology, IPS Academy College of Pharmacy, Rajendra Nagar A.B. Road Indore 452012 (M.P.).

***Corresponding Author: Dr. D. K. Jain**

Department of Pharmacology, IPS Academy College of Pharmacy, Rajendra Nagar A.B. Road Indore 452012 (M.P.).

Email ID: principal.coph@ipsacademy.org

Article Received on 09/01/2025 **Article Revised on 30/01/2025** **Article Published on 20/02/2025**

ABSTRACT

Pharmacovigilance is essential for guaranteeing the safety and effectiveness of vaccines and treatments, especially during the monkeypox crisis. Since monkeypox has recently spread outside of endemic areas, it is imperative to employ antivirals such as Tecovirimat and Brincidofovir as well as immunizations like Modified Vaccinia Ankara (MVA-BN, JYNNEOS) as soon as possible. These emergency therapies require robust post-marketing surveillance to detect adverse drug reactions (ADRs) and ensure public safety. Some challenges include a lack of real-world safety data, inconsistent global reporting methods, and underreporting of ADRs. Pharmacovigilance supports regulatory compliance, aids in risk-benefit evaluations, and encourages public health communication in the fight against vaccine reluctance and misinformation. International collaboration, particularly between the FDA, EMA, and WHO, is necessary to harmonize reporting standards and exchange safety data. Furthermore, advanced technologies like artificial intelligence and big data analytics, which allow for the early detection of safety signals, enhance pharmacovigilance capabilities. This analysis highlights pharmacovigilance's critical role in safeguarding public health and managing the monkeypox outbreak through continued monitoring and international cooperation.

KEYWORDS: Pharmacovigilance, Monkeypox, Vaccine Safety, Adverse Drug Reactions, Public Health, Regulatory Compliance.

1. INTRODUCTION TO PHARMACOVIGILANCE

Pharmacovigilance is the field dedicated to identifying, evaluating, comprehending, and preventing adverse drug reactions (ADRs) and other issues related to drug use. By identifying, monitoring, and managing any risks that may emerge after a medication is placed on the market, pharmacovigilance aims to promote the safe and effective use of pharmaceuticals. Although clinical studies play a key role in assessing a drug's safety, many adverse effects may only become apparent when a larger population uses the drug. Pharmacovigilance is therefore necessary for studying drug safety outside of clinical trials (Salem et al., 2015).

It encompasses a wide range of activities, including risk management, signal detection, and collecting ADR reports. Any adverse drug reactions (ADRs) that occur when a medication is taken as prescribed are referred to as ADRs. The majority of adverse drug reactions (ADRs) are mild and temporary, but some can be serious and result in hospitalization or even death (Heckman et al., 2015).

Post-market surveillance, a crucial aspect of pharmacovigilance, guarantees that medications are regularly assessed by the general population after release. Keeping an eye out for long-term impacts that pre-marketing studies could have missed is part of this. A global network of regulatory agencies oversees pharmacovigilance. The World Health Organization (WHO), which uses the Vigi-Base database and the Uppsala Monitoring Center to monitor worldwide pharmacovigilance, is among the leading organizations. This database, which includes individual case safety reports from countries worldwide, enables the identification of safety signal trends that suggest a possible connection between a medication and a side effect (WHO, 2014).

The FDA plays a key role in the U.S. through the FDA Adverse Event Reporting System (FAERS) database, which helps uncover new safety concerns, and the MedWatch program, which collects reports of adverse events (FDA, 2020). The signal detection process is a crucial part of pharmacovigilance and involves identifying potential risks that may manifest when the drug is used. To identify unexpected patterns that could indicate new safety concerns, large volumes of adverse event data are regularly sorted using techniques like statistical analysis and data mining (Evans et al., 2011). A thorough risk-benefit analysis is conducted after a

signal has been identified to see whether the drug's benefits still outweigh its drawbacks. Based on the findings, regulatory agencies may recommend actions such as changing the product label, releasing cautions, or even removing the drug from sale (Jenkins et al., 2017). Risk management is another essential element of pharmacovigilance. This involves assessing the likelihood and severity of a drug's potential risks and implementing safety measures to reduce patient injury. Modified dosage guidelines, use limitations for particular populations, or the development of Risk Management Plans (RMPs), which provide structured processes for lowering pharmaceutical dangers, are some examples of these strategies (Heckman et al., 2015). All things considered, pharmacovigilance ensures that drugs are regularly examined for safety for their whole lifecycle. Its integration with the healthcare system is crucial for identifying potential risks that could jeopardize patients' health. The growing use of digital platforms and databases has revolutionized pharmacovigilance and enhanced the ability to identify and manage drugs by enabling real-time data collection and analysis.



Fig. 1: Pharmacovigilance Roles.

2. Importance in Emerging Infectious Diseases

Pharmacovigilance is crucial to guarantee the efficacy and safety of medications used to treat emerging infectious diseases (EIDs). The fast introduction of new infectious agents such as Zika, Ebola, and SARS-CoV-2 necessitates the widespread and immediate use of therapeutic medications, sometimes with compassionate use programs or emergency use authorizations. Since there are often no established treatment guidelines for EIDs, pharmacovigilance is crucial to ensuring the safety of drugs and vaccines created in response to these conditions. This means keeping an eye out for adverse drug reactions (ADRs), controlling the risks associated with newer medications, and spotting new safety signals (Alvaro et al., 2020).



Fig. 2: Emerging Infectious Diseases.

2.1 Early Identification of Adverse Drug Reactions (ADR)

Regarding EIDs, one of the most crucial roles of pharmacovigilance is the early detection of adverse drug responses. Because of the novelty of the pathogens and the urgency of responding, treatments for emerging infections are often administered quickly with limited pre-market safety data. During the 2014–2016 Ebola outbreak, for example, investigational drugs such as ZMapp, Favipiravir, and Remdesivir were used without first completing clinical studies. These treatments were used in response to preliminary findings and when no alternative therapeutic options were available (Sissoko et al., 2017).

Pharmacovigilance systems help detect any unanticipated side effects or safety concerns that may arise with the widespread use of medications employing patient monitoring, registries, and spontaneous ADR reporting. For instance, during the COVID-19 pandemic, vaccines like Pfizer-Biotech and Moderna were developed swiftly and dispersed globally. Pharmacovigilance platforms, such as the Vaccine Adverse Event Reporting System (VAERS), have facilitated the early detection of ADRs like myocarditis in younger populations (Mevorach et al.,

2021). The timely collection and analysis of this data allowed regulatory agencies to take the appropriate actions, such as advising who should have the vaccine and under what conditions.

Fig. 3: Identification of ADR's.

2.2 Risk Management in Novel Therapies

Pharmacovigilance also aids in risk management while treating recently identified pathogens. Novel medications sometimes have unclear long-term safety profiles that can only be ascertained by real-world data after a significant number of patients have taken the drug. For example, the use of hydroxychloroquine to treat COVID-19 was re-examined after pharmacovigilance data indicated potential cardiovascular and renal risks (Mekonnen et al., 2020). Continuous monitoring allowed regulatory agencies to change treatment recommendations, reducing unnecessary exposure to drugs with unacceptable risks. Another component of risk management strategies is the development of Risk Management Plans (RMPs), which are designed to recognize and lessen the risks associated with the use of a particular medicine. These tactics could include patient education, restricted use in particular populations, or careful monitoring for negative effects (Hauss et al., 2020).

Fig. 4: Risk Management in Novel Therapies.

2.3 Importance in Global Health Responses

In addition, to guarantee the immediate safety of the therapies being used, pharmacovigilance is crucial in defining how the global health system reacts to newly emerging infectious diseases. A better understanding of how drugs and vaccines function in many populations, regions, and medical settings is made possible by global data collection. This data is particularly useful when analyzing the equity of access to life-saving treatments in settings with limited resources, where pharmacovigilance programs may be less robust. Additionally, pharmacovigilance systems help identify faulty or fake drugs, which is a common issue during disease outbreaks. High-quality data must be promptly made available to the public for them to receive safe and efficient therapies. During epidemics, when demand for medical supplies usually outpaces, this is particularly crucial (Griffiths et al., 2020).

Fig. 5: Importance in Global Health Response.

2.4 Facilitating Regulatory Decision-Making

Pharmacovigilance data supports regulatory decision-making by providing the evidence needed to assess the benefit-risk profile of drugs and vaccines. Organizations like the FDA, EMA, and WHO use post-market monitoring data to guide safe use, make recommendations, and, if necessary, limit or halt the use of hazardous products. The efficient pharmacovigilance systems in place for EID reactions allow for quick regulatory actions, protecting public health during international health emergencies (Bukar et al., 2021).



Fig. 6: Regulatory Decision Making.

3. MONKEYPOX VIRUS OVERVIEW

3.1 In-Depth Analysis of the Monkeypox Virus

Monkeypox is caused by the monkeypox virus (MPXV), a zoonotic viral disease belonging to the Orthopoxvirus genus of the Poxviridae family. Since its discovery in laboratory monkeys in 1958 and the first human case in the Democratic Republic of the Congo (DRC) in 1970, monkeypox has gained global attention as a re-emerging infectious disease. While it had previously been confined to the rainforests of Central and West Africa, the 2022 global outbreak demonstrated its ability to spread anywhere, posing a significant threat to public health (Bunge et al., 2022). The virus typically causes less serious illness, although it is identical to the variola virus that causes smallpox. However, its high morbidity and rapid spread underscore the importance of understanding its virology, method of transmission, clinical features, and therapeutic options.



Fig. 7: Monkeypox Virus Overview.

3.2 Pathophysiology and Virology

The monkey pox virus (MPXV), an enveloped, double-stranded DNA virus, exists in two genetically distinct clades: the Congo Basin clade, which is linked to higher transmissibility and mortality, and the West African clade, which leads to a milder form of the disease. MPXV replicates within the cytoplasm of host cells and is capable of infecting various hosts, including rodents and primates (CDC, 2022).Through initial replication at the point of entry and subsequent lymphatic system dispersion, the pathogenesis involves viremia. The virus triggers an inflammatory immune response, which results in the characteristic systemic symptoms and rash. Serious sickness is more likely to strike people with compromised immune systems.



Fig. 8: Pathophysiology of Monkeypox Virus.

3.3 Transmission

Monkeypox is mostly transmitted by –

1. Animal-to-human contact, can occur when people handle sick animals (such as monkeys or rodents), consume jungle meat, or come into contact with animal waste.
2. Person-to-person transmission occurs through respiratory droplets during prolonged, close contact, as well as direct contact with an infected individual's skin lesions, bodily fluids, or scabs. Contaminated objects, like clothing or bedding, can also spread the virus. The 2022 outbreak highlighted the possibility of sexual transmission, as it predominantly affected men who have sex with men (MSM). Enhanced surveillance indicates that the virus can be transmitted through close physical contact during sexual activities (WHO, 2022).



Fig. 9: Transmission of Monkeypox Virus.

3.4 Epidemiology

Once endemic in Central and West Africa, monkeypox has been increasingly spreading to non-endemic countries due to globalization, increased human-wildlife contact, and decreased immunity to smallpox after smallpox vaccination campaigns ended. The case fatality rate (CFR) differs between clades; the Congo Basin clade can have a CFR as high as 10%, while the CFR for the West African clade is under 3%. In the 2022 global outbreak, more than 85,000 cases were reported across 110 countries, with the majority occurring in Europe and the Americas. Unlike past outbreaks tied to zoonotic spillover, the 2022 outbreak was primarily driven by human-to-human transmission (Bunge et al., 2022).



Fig. 10: Epidemiology of Monkeypox Virus.

3.5 Clinical Manifestations

Monkeypox develops over 5-21days and goes through 2 separate phases:

1. **Prodromal Phase**: This phase is characterized by symptoms such as fever, chills, headache, fatigue, muscle aches, and lymphadenopathy, the latter being a key distinguishing feature from other conditions that mimic smallpox or chickenpox.
2. **Rash Phase**: Starting 1-3 days after fever onset, the rash begins with maculopopular lesions and progresses to crusted scabs, vesicles, and pustules. Those who are immunocompromised, pregnant, or children are at higher risk for severe illness and complications, including secondary bacterial infections, respiratory issues like bronchopneumonia, sepsis, encephalitis, keratitis, and potential vision loss. The rash typically starts on the face, hands, and feet, then spreads to other body areas, including mucous membranes (Yinka-Ogunleye et al., 2018).



Fig. 11: Clinical Manifestations of Monkeypox Virus.

3.6 Diagnosis: The diagnosis requires scientific evidence since monkeypox can mimic other illnesses that mimic pox. Diagnostic methods include:

1. **Polymerase Chain Reaction (PCR)**: This is considered the most reliable method for detecting MPXV - DNA in lesion samples.
2. **Electron Microscopy**: This technique allows for the visualization of viral particles in clinical specimens.
3. **Serology:** While it detects antibodies, it cannot distinguish MPXV from other orthopoxviruses.
4. **Viral Isolation:** Viruses are isolated in specialized biosafety facilities.

3.7 Treatment

The majority of monkeypox cases go away on their own, but severe cases require medical care. Today's current therapy options include:

1. Supportive Care: Addresses subsequent bacterial infections, eases pain, and concentrates on minimizing symptoms and managing outcomes.

2. Antiviral Treatments

a. Tecovirimat (TPOXX): This drug is authorized for monkeypox treatment under emergency protocols. It works by inhibiting the VP37 protein, which is essential for viral release and replication. Clinical data supports its effectiveness in reducing lesion duration and preventing complications (Adler et al., 2022).

b. Brincidofovir and Cidofovir: These broad-spectrum antivirals target DNA polymerase and are considered treatment options for severe cases, though they are linked to nephrotoxicity and other adverse effects.

c. Immunoglobulin Therapy: Vaccination immune globulin (VIG) may be helpful for patients with severe immunodeficiency.

Fig. 12: Causes, Diagnosis, and Treatment of Mpox.

3.8 Vaccination: Vaccination is a significant factor in preventing monkeypox. Two vaccines used in the smallpox eradication program have been modified:

1. **Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN),** also referred to as Jynneos, Imvanex, or Imvamune, is a non-replicating vaccine with a strong safety profile, approved for preventing monkeypox in high-risk groups.
2. **ACAM-2000:** a vaccine with great immunity and replication potential, but a higher risk of adverse effects, such as myocarditis.

Vaccination strategies involve pre-exposure prophylaxis (PrEP) for healthcare workers and post-exposure prophylaxis (PEP) within four days of exposure to lessen the severity of symptoms (CDC, 2022).

3.9 Public Health Implications and Prevention: Effective monkeypox prevention requires a range of public health initiatives, such as:

1. **Surveillance and Early Detection:** Global surveillance networks have been strengthened to identify outbreaks and track the spread of viruses.
2. **Campaigns to raise public awareness:** teaching about the risks of transmission, hygiene, and appropriate animal handling in endemic areas.
3. **Vaccination Programs:** Aimed at high-risk populations, including healthcare workers, those with compromised immune systems, and close family members of confirmed cases.
4. **Isolation and quarantine:** To prevent the spread, isolate sick individuals and locate contacts.

3.10 Challenges and Opportunities: The global reaction to monkeypox has highlighted several issues:

- **Limited Vaccine Access:** In endemic regions of Africa, access to vaccinations and antivirals is significantly restricted.
- **Lack of Awareness:** Inaccurate diagnosis and delayed detection complicate epidemic management efforts.
- **Changing Transmission Dynamics:** The function of sexual transmission and asymptomatic cases needs further research. Future studies on MPXV's pathophysiology and immune responses ought to be more extensive.
- Developing more targeted therapies with fewer side effects
- Expanding more equitable access to immunizations and treatments around the globe.

Fig. 13: Vaccination for MPOX.

4. Role of PV in Monkeypox

4.1 Overview

Monkeypox, a zoonotic viral disease caused by the monkeypox virus (MPXV), has gained significant attention because of its potential to spread beyond endemic regions. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) emphasize the importance of thorough surveillance and safety monitoring for vaccinations and treatments used in managing monkeypox. Pharmacovigilance, which involves identifying, evaluating, understanding, and preventing adverse drug reactions, is vital for safely and effectively using therapies.

4.2 Monitoring Vaccine Safety

4.2.1 Surveillance of Adverse Events Following Immunization (AEFI)

Monitoring and evaluating adverse events following immunization (AEFI) is a key component of vaccine pharmacovigilance, which aims to maintain public trust and ensure vaccine safety. Modified Vaccinia Ankara (MVA-BN, JYNNEOS/Imvanex/Imvamune), a plague-free smallpox vaccine that does not replicate, also authorized for monkeypox, is one of the primary vaccines used to prevent the disease. Although it can prevent monkeypox, the live attenuated smallpox vaccine ACAM2000 carries higher risks, especially for those with compromised immune systems. Both vaccines undergo rigorous post-marketing surveillance through global pharmacovigilance databases such as Eudra-Vigilance and the Vaccine Adverse Event Reporting System (VAERS) to monitor plague-free adverse reactions, including:

- Injection site reactions (pain, swelling, erythema)
- Systemic symptoms, including fever, fatigue, and headache
- Infrequent but serious adverse effects, like myocarditis (more prevalent with ACAM2000)

4.2.2 Risk-Benefit Analysis

To ascertain the overall safety profile of monkeypox vaccines, pharmacovigilance systems perform ongoing risk-benefit analysis, and real-world data gathered from vaccinated populations aid in updating recommendations, contraindications, and risk-reduction tactics.

4.2.3 Special Populations and Long-Term Safety

Monitoring vaccine effects in special populations (immunocompromised individuals, pregnant women, children) is critical. Pharmacovigilance ensures that data on long-term safety and efficacy are collected and analyzed to refine immunization policies.

Fig. 14: Monitoring Vaccine Safety.

4.3 Assessing Therapeutic Interventions

4.3.1 Pharmacovigilance for Antiviral Treatments

While there is currently no specific plague-free antiviral drug licensed for monkeypox, repurposed drugs such as Tecovirimat (TPOXX), Brincidofovir, and Cidofovir are being used under regulatory oversight. Pharmacovigilance uses empirical data and clinical trials to track their safety profiles:

- **Tecovirimat (TPOXX):** FDA-approved for smallpox but off-label for monkeypox. It is common to hear about side effects including headache and nausea.
- **Brincidofovir:** a lipid-conjugated version of cidofovir that is safer but has been associated with hepatotoxicity. One broad-spectrum antiviral that should be closely monitored for nephrotoxic effects is cidofovir.

4.3.2 Drug-Drug Interactions and Contraindications

Pharmacovigilance systems look for possible drug-drug interactions, especially in patients with comorbidities who are taking multiple medications. Continuous safety assessments help avoid adverse effects caused by co-occurring drug use.

4.3.3 Off-Label Use and Compassionate Use Programs

In emergencies, off-label drug use and compassionate use programs are necessary. Pharmacovigilance plays a role in assessing efficacy and safety to support evidence-based decision-making.

Fig. 15: Assessing Therapeutic Interventions.

4.4 Ensuring Regulatory Compliance

4.4.1 Emergency Use Authorizations (EUAs)

Regulatory bodies such as the FDA, EMA, and WHO grant EUAs for monkeypox vaccines and treatments. To ensure compliance with safety and efficacy standards, pharmacovigilance collects post-marketing data, updates prescribing information, and recommends risk reduction strategies.

4.4.2 Practical Proof and After-Marketing Tracking: Long-term safety monitoring with technologies like VigiBase and MedWatch identifies new risks and leads to regulatory revisions, including product deletions or label changes.

4.4.3 Signal detection and risk management: Pharmacovigilance systems use signal detection algorithms to detect potential safety issues so that regulatory agencies can take timely action, such as issuing safety alerts, restricting use in vulnerable populations, or recommending more research.

5. Public Health Communication

5.1 Addressing Vaccine Hesitancy and Misinformation

Safety data must be presented in an intelligible and transparent way to dispel vaccine hesitancy. The timely dissemination of accurate safety updates, public engagement through educational programs, and collaboration with the media and medical professionals to counteract misinformation are all made possible by pharmacovigilance.

5.2 Enhancing ADR Reporting and Public Involvement

By developing digital platforms and mobile applications for real-time data collection, making reporting tools easily accessible to the general public and medical professionals, and planning awareness campaigns to increase ADR reporting rates, pharmacovigilance encourages ADR reporting.

6. Global Collaboration in Pharmacovigilance

6.1 International Pharmacovigilance Networks

Collaboration among international organizations improves pharmacovigilance programs.

One key player is the **WHO Programme for International Drug Monitoring (PIDM),** which enhances ADR monitoring worldwide.

Uppsala Monitoring Center (UMC): Develops tools for global pharmacovigilance data sharing.

EMA and CDC: Work together with national health agencies to enhance safety surveillance.

6.2 Addressing Inequalities in Pharmacovigilance

In poor nations, the lack of infrastructure often makes ADR reporting challenging. International collaboration facilitates the development of standardized pharmacovigilance systems in endemic regions.

6.3 Coordinated Global Reaction

Real-time data sharing between countries enables coordinated safety assessments, expedited regulatory decisions, and effective reaction strategies.

7. Future Directions and Challenges

7.1 Making Use of Big Data and Artificial Intelligence (AI)

By enhancing real-time monitoring, predictive analytics, and signal identification, AI-powered pharmacovigilance solutions improve safety assessments.

7.2 Strengthening the Pharmacovigilance Infrastructure
Investing in digital reporting platforms, training programs, and healthcare systems is necessary to strengthen global pharmacovigilance frameworks.

7.3 Addressing the Problem of Underreporting: ADR underreporting is a significant issue. Actively encouraging patients and medical personnel to report adverse medication responses can improve data collection and decision-making.

8. Challenges in Pharmacovigilance for Monkeypox
The zoonotic virus that causes monkeypox, a condition that has grown to be a serious worldwide health concern, is called the monkeypox virus (MPXV). The monkeypox outbreak in non-endemic locations has made the use of vaccines such as Modified Vaccinia Ankara (MVA-BN, JYNNEOS) and ACAM2000, as well as antiviral drugs such as Tecovirimat (TPOXX) and Brincidofovir, essential. Robust pharmacovigilance systems are required to ensure the safety and effectiveness of different medicinal treatments. However, a variety of problems, including varied reporting criteria, underreporting of adverse drug reactions (ADRs), and limitations on data collecting, make effective pharmacovigilance for monkeypox difficult.

8.1 Challenges in Data Collection
8.1.1 Lack of Standardized Surveillance Systems
One of the biggest challenges to monkeypox pharmacovigilance is the lack of standardized surveillance methods. Many countries lack established pharmacovigilance infrastructures, which results in uneven data collecting and reporting. This makes appropriately monitoring the safety of drugs and vaccinations more challenging.

8.1.2 Limited Real-World Data
Since some regions have authorized monkeypox vaccinations and treatments under emergency use provisions, there is a dearth of real-world safety data. Pharmacovigilance primarily relies on post-marketing surveillance to identify rare or persistent side effects; however, the information on monkeypox treatments is still insufficient for comprehensive safety evaluations.

8.1.3 Challenges in Electronic Health Records (EHR) Integration
Real-time data collection on adverse drug reactions (ADRs) and vaccine safety requires electronic health records or EHRs. However, due to variations in health informatics infrastructure between nations, pharmacovigilance database integration with national EHR systems continues to be a major difficulty.

8.1.4 Insufficient Funding and Resources
Effective pharmacovigilance systems require substantial human and financial resources to establish and maintain. Low- and middle-income countries (LMICs) have long had endemic monkeypox, but these countries often lack the resources necessary to establish comprehensive safety monitoring systems.

8.2 Underreporting of Adverse Events:
8.2.1 Low Awareness among Healthcare Professionals and Patients
The underreporting of adverse drug reactions (ADRs) and vaccine-related occurrences is a significant problem in pharmacovigilance. Patients may be unwilling to report moderate side effects or uninformed of reporting procedures, and healthcare personnel may not consistently prioritize or identify ADR reporting.

8.2.2 Fear of Vaccine Hesitancy and Misinformation
Governments and health authorities are hesitant to provide adverse drug reaction (ADR) data because they worry that side effect reports may encourage vaccine skepticism and disinformation. The public's mistrust may grow as a result of this reluctance to openly share bad event data.

8.2.3 Reliance on Passive Surveillance Systems
Many pharmacovigilance systems rely on passive surveillance, such as spontaneous ADR reporting through the **Vaccine Adverse Event Reporting System (VAERS)** or **Eudra-Vigilance**. These systems depend on voluntary reporting, which leads to significant underreporting and data gaps.

8.2.4 Stigma and Socioeconomic Barriers: In some regions, there is a stigma associated with seeking healthcare for monkeypox due to its association with certain populations or modes of transmission. This can discourage patients from reporting adverse events related to vaccines and treatments.

8.3 Variability in Reporting Standards
8.3.1 Lack of Harmonized Global Pharmacovigilance Policies
Different countries follow varying pharmacovigilance guidelines, making it difficult to compare safety data across regions. While WHO's **VigiBase** attempts to centralize ADR reporting, there is still a lack of uniformity in the way data is collected and analyzed.

8.3.2 Differences in Regulatory Requirements
Regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), and WHO have different requirements for ADR reporting and risk assessment. These inconsistencies make it challenging to conduct comparative analysis and global safety assessments.

8.3.3 Variations in Definition of Adverse Events
The definition and classification of adverse events vary across different regulatory agencies. For example, what one country considers a "serious" adverse event may not be classified the same way in another region, leading to discrepancies in reporting.

8.3.4 Language and Cultural Barriers

In global pharmacovigilance efforts, language barriers and cultural differences can affect ADR reporting. Some healthcare professionals may lack access to reporting tools in their native language, while cultural differences in patient attitudes toward medication side effects may influence reporting behavior.

8.4 Strategies to Address These Challenges

8.4.1 Strengthening Active Surveillance Systems

Active surveillance, such as sentinel surveillance programs and cohort event monitoring, should be integrated into pharmacovigilance efforts to complement passive reporting.

8.4.2 Expanding Public and Healthcare Professional Education

Raising awareness among healthcare providers and the public on the significance of reporting adverse drug reactions (ADR), can improve pharmacovigilance data collection. Educational campaigns and digital tools can facilitate easier reporting mechanisms.

8.4.3 Enhancing International Collaboration: Global cooperation through organizations like WHO, EMA, and CDC is essential for establishing harmonized pharmacovigilance standards and improving data-sharing mechanisms.

8.4.4 Leveraging Artificial Intelligence (AI) and Big Data Analytics

AI-powered pharmacovigilance tools can enhance the efficient detection of safety signals. Machine learning algorithms can process vast datasets to uncover emerging risks and trends in adverse drug reaction (ADR) reporting.

8.4.5 Implementing Standardized Reporting Frameworks

Developing standardized ADR reporting frameworks that align with global health organizations can reduce variability in safety assessments and improve comparability across regions.

9. CONCLUSION

Pharmacovigilance serves as the cornerstone of drug safety in the context of Monkeypox virus treatment and prevention. The use of repurposed antivirals and vaccines, coupled with limited clinical trial data, elevates the need for robust pharmacovigilance practices. Continuous monitoring of ADRs, active surveillance, and global collaboration are essential to identify potential safety concerns promptly. Strengthening pharmacovigilance infrastructure ensures that emerging safety signals are addressed effectively, supporting evidence-based therapeutic decisions. As Monkeypox outbreaks expand globally, integrating pharmacovigilance into public health responses is crucial for optimizing drug safety, protecting patient health, and guiding regulatory policies.

10. REFERENCES

1. Evans SJ, et al. Pharmacovigilance: Principles and Practice. Br J Clin Pharmacol, 2011; 72(6): 1009-18.
2. Heckman MG, et al. Pharmacovigilance and Drug Safety: Regulatory Framework and Surveillance. Am J Health Syst Pharm., 2015; 72(9): 678-84.
3. Jenkins AJ, et al. Pharmacovigilance: Current Challenges and Future Directions. J Clin Pharmacol, 2017; 57(9): 1141-51.
4. Salem DE, et al. Adverse Drug Reactions and Pharmacovigilance: Principles and Practices. J Pharm Sci., 2015; 104(9): 2790-9.
5. World Health Organization (WHO). Pharmacovigilance: A Short Course on the Safety of Medicines. WHO website, 2014.
6. U.S. Food and Drug Administration (FDA). The FDA's Role in Pharmacovigilance. FDA website, 2020.
7. Alvaro A, et al. The Role of Pharmacovigilance in Emerging Infectious Diseases: A Critical Review. Int J Clin Pharmacol Ther., 2020; 58(10): 512-20.
8. Bukar M, et al. Global Pharmacovigilance for Emerging Infectious Diseases: Role in Pandemic Preparedness. Lancet Infect Dis., 2021; 21(3): 324-31.
9. Griffiths C, et al. The Impact of Pharmacovigilance on the Response to the Ebola Virus Disease Outbreak. Int J Epidemiol, 2020; 49(4): xxx-xxx.
10. Hauss M, et al. Pharmacovigilance Systems in Emerging Infectious Diseases: Monitoring the Safety of Novel Vaccines and Drugs. Clin Pharmacokinet, 2020; 59(4): 419-33.
11. Mekonnen D, et al. Hydroxychloroquine for COVID-19: Pharmacovigilance and Risk Assessment. Drug Saf., 2020; 43(10): 1023-9.
12. Mevorach D, et al. Myocarditis after COVID-19 Vaccination in Israel. N Engl J Med., 2021; 385: 2140-9.
13. Sissoko D, et al. Outbreak of Ebola Virus Disease in Guinea: Implications for Public Health. Lancet Infect Dis., 2017; 17(5): 481-5.
14. Adler H, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis., 2022; 22(2): 105-15. DOI: 10.1016/S1473-3099(21)00292-8.
15. Bunge EM, et al. The changing epidemiology of human monkeypox—A potential threat? PLoS Negl Trop Dis., 2022; 16(2): e0010141. DOI: 10.1371/journal.pntd.0010141.
16. Centers for Disease Control and Prevention (CDC). Monkeypox: Clinical Recognition. CDC website, 2022.
17. World Health Organization (WHO). Monkeypox. WHO website, 2022.
18. Yinka-Ogunleye A, et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis., 2018; 19(8): 872-9. DOI: 10.1016/S1473-3099(19)30294-4.

19. World Health Organization (WHO). Monkeypox Outbreak: Global Health Emergency. WHO website, 2022.
20. Centers for Disease Control and Prevention (CDC). Monkeypox Vaccination and Treatment Guidelines. CDC website, 2022.
21. European Medicines Agency (EMA). Vaccine Safety Surveillance for Monkeypox. EMA website, 2022.
22. World Health Organization (WHO). Pharmacovigilance in Emerging Infectious Diseases. WHO website, 2022.
23. Centers for Disease Control and Prevention (CDC). Adverse Event Reporting for Monkeypox Vaccination. CDC website, 2022.
24. European Medicines Agency (EMA). Monitoring Vaccine Safety in the EU. EMA website, 2022.
25. Uppsala Monitoring Centre. Global Pharmacovigilance and Data Standardization. UMC website, 2022.
26. Petersen E, et al. Vaccine Safety During Monkeypox Outbreak. Lancet Infect Dis., 2022; 22(11): 1360-8.
27. Rao R, et al. Safety Surveillance of Tecovirimat in Monkeypox Treatment. J Antiviral Res., 2022; 200: 105-12.
28. Chen N, et al. Post-Marketing Surveillance of MVA-BN Vaccine. Vaccine., 2021; 39(45): 6782-9.
29. Mahase E. Challenges in Pharmacovigilance for Emerging Infections. BMJ., 2022; 377: e070920.
30. Li Y, et al. Global Collaboration in Pharmacovigilance: Lessons from Monkeypox. Int J Infect Dis., 2022; 122: 48-54.
31. Krause PR, et al. The Role of Pharmacovigilance in Pandemic Response. N Engl J Med., 2021; 385(24): 2149-57.